MedTrace Logo

Topiramate Augmentation in Bulimia Nervosa Partial Responders

NCT00988481 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-07-15

No results posted yet for this study

Summary

The goal of this study is to generate pilot data exploring the addition of an augmentation (additional) medication to patients suffering from bulimia nervosa who have responded but not had complete symptom resolution with a course of standard medication treatment.

Conditions

  • Bulimia Nervosa

Interventions

DRUG

Topiramate

Topiramate titrated to 200mg/day over four weeks, for ten weeks

Sponsors & Collaborators

  • Neuropsychiatric Research Institute, Fargo, North Dakota

    lead OTHER

Principal Investigators

  • James L Roerig, PharmD, BCPP · Neuropsychiatric Research Institute, University of North Dakota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988481 on ClinicalTrials.gov